Otonomy, Inc. Logo
Otonomy to Participate in the H.C. Wainwright Global Investment Conference
May 18, 2022 07:30 ET | Otonomy, Inc.
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
Otonomy, Inc. Logo
Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting
May 12, 2022 07:30 ET | Otonomy, Inc.
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy, Inc. Logo
Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 09, 2022 16:04 ET | Otonomy, Inc.
Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected...
Otonomy, Inc. Logo
Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update
May 02, 2022 07:30 ET | Otonomy, Inc.
SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will...
Otonomy, Inc. Logo
Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss
April 20, 2022 07:30 ET | Otonomy, Inc.
Clinical benefit again observed for OTO-413 versus placebo for multiple efficacy endpoints based on responder analysis at both Days 57 and 85 Results support clinical activity and tolerability...
Otonomy, Inc. Logo
Otonomy to Host Virtual Investor R&D Event on March 22, 2022
March 15, 2022 07:30 ET | Otonomy, Inc.
SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
February 28, 2022 16:27 ET | Otonomy, Inc.
OTO-313 Phase 2 trial in tinnitus fully enrolled ahead of schedule with top-line results expected in mid-2022; initiating safety evaluation of higher and bilateral dosingOTO-413 Phase 2a cohort in...
Otonomy, Inc. Logo
Otonomy to Participate in Two Upcoming Investor Conferences
February 28, 2022 07:30 ET | Otonomy, Inc.
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy to Host Virtual Investor R&D Event on March 22, 2022
February 25, 2022 07:30 ET | Otonomy, Inc.
SAN DIEGO, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus
February 22, 2022 07:30 ET | Otonomy, Inc.
OTO-313 Phase 2 trial is fully enrolled ahead of scheduleTop-line results for all timepoints expected in mid-2022 SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a...